NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $13.18 -0.22 (-1.64%) (As of 10:30 AM ET) Add Compare Share Share Today's Range$12.99▼$13.6150-Day Range$7.65▼$14.8952-Week Range$2.55▼$16.50Volume269,569 shsAverage Volume705,931 shsMarket Capitalization$1.28 billionP/E RatioN/ADividend YieldN/APrice Target$22.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ARS Pharmaceuticals alerts: Email Address ARS Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside72.6% Upside$22.75 Price TargetShort InterestBearish20.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 25 Articles This WeekInsider TradingSelling Shares$5.61 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.66) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector596th out of 924 stocksPharmaceutical Preparations Industry269th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.86% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently increased by 13.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRY. Previous Next 2.9 News and Social Media Coverage News SentimentARS Pharmaceuticals has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for ARS Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest16 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 129% compared to the previous 30 days.MarketBeat Follows16 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,609,379.00 in company stock.Percentage Held by Insiders40.10% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ARS Pharmaceuticals are expected to decrease in the coming year, from ($0.66) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -25.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -25.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ARS Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Angel PublishingWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. About ARS Pharmaceuticals Stock (NASDAQ:SPRY)ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Read More SPRY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRY Stock News HeadlinesAugust 22 at 9:51 AM | insidertrades.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 10,000 Shares of StockAugust 22 at 6:20 AM | markets.businessinsider.comStrong Buy Rating for ARS Pharma on Neffy’s Market Potential and Strategic LaunchAugust 22, 2024 | Paradigm Press (Ad)US developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will create the greatest investment opportunity for Americans since WWII. Similar stocks in the past have seen peak gains of 16,270%in just 18 months.August 22 at 6:20 AM | finance.yahoo.comARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 SharesAugust 21 at 8:31 AM | msn.comCantor Fitzgerald Initiates Coverage of ARS Pharmaceuticals (SPRY) with Overweight RecommendationAugust 21 at 4:16 AM | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated at Cantor FitzgeraldAugust 20 at 8:03 PM | msn.comARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' AnalystAugust 20 at 9:22 AM | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Buy" from BrokeragesAugust 22, 2024 | Paradigm Press (Ad)US developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will create the greatest investment opportunity for Americans since WWII. Similar stocks in the past have seen peak gains of 16,270%in just 18 months.August 18, 2024 | finance.yahoo.comSPRY Sep 2024 2.500 call (SPRY240920C00002500)August 15, 2024 | finance.yahoo.comInsider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY)August 15, 2024 | americanbankingnews.comFY2024 Earnings Estimate for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Issued By Leerink PartnrsAugust 14, 2024 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected to Earn FY2025 Earnings of ($0.64) Per ShareAugust 14, 2024 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 1-Year High Following Analyst UpgradeAugust 14, 2024 | msn.comRaymond James Upgrades ARS Pharmaceuticals (SPRY)August 14, 2024 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up Following Analyst UpgradeAugust 13, 2024 | seekingalpha.comWall Street Breakfast Podcast: CXApp Surges On Google Cloud DealAugust 13, 2024 | msn.comLexicon to cut 50% of workforce to focus on sotagliflozinSee More Headlines Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today8/22/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRY CUSIPN/A CIK1671858 Webars-pharma.com Phone206-456-2900FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$22.75 High Stock Price Target$30.00 Low Stock Price Target$19.00 Potential Upside/Downside+68.5%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax Margin-8,968.40% Return on Equity-19.77% Return on Assets-19.26% Debt Debt-to-Equity RatioN/A Current Ratio32.82 Quick Ratio32.82 Sales & Book Value Annual Sales$30,000.00 Price / Sales43,623.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book5.63Miscellaneous Outstanding Shares96,940,000Free Float58,040,000Market Cap$1.31 billion OptionableOptionable Beta0.87 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Richard Lowenthal M.B.A. (Age 58)M.S., MSMSEL, Founder, President, CEO & Director Comp: $2.75MDr. Sarina Tanimoto M.B.A. (Age 55)M.D., Co-Founder & Chief Medical Officer Comp: $2.47MMr. Alexander A. Fitzpatrick Esq. (Age 57)Chief Legal Officer & Secretary Comp: $677.14kDr. Robert Bell Ph.D.Co-Founder & Chief Science OfficerMs. Kathleen D. Scott CPAChief Financial OfficerMr. Brian T. Dorsey M.S. (Age 55)Chief Operations Officer Mr. Daniel RelovskySenior Vice President of MarketingMr. Harris Kaplan M.B.A. (Age 72)Executive Vice President of Commercial Strategy Mr. Eric Karas (Age 51)Chief Commercial Officer Comp: $618.61kMr. Justin Chakma (Age 34)Chief Business Officer & Secretary More ExecutivesKey CompetitorsKrystal BiotechNASDAQ:KRYSOrganon & Co.NYSE:OGNNuvalentNASDAQ:NUVLBridgeBio PharmaNASDAQ:BBIOApellis PharmaceuticalsNASDAQ:APLSView All CompetitorsInsiders & InstitutionsRichard E LowenthalSold 100,000 sharesTotal: $1.50 M ($15.03/share)Kathleen D ScottSold 12,500 sharesTotal: $200,000.00 ($16.00/share)Brian DorseySold 50,000 sharesTotal: $750,000.00 ($15.00/share)Eric KarasSold 10,000 sharesTotal: $140,000.00 ($14.00/share)Susquehanna International Group LLPBought 33,600 shares on 8/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SPRY Stock Analysis - Frequently Asked Questions How have SPRY shares performed this year? ARS Pharmaceuticals' stock was trading at $5.48 on January 1st, 2024. Since then, SPRY shares have increased by 140.5% and is now trading at $13.18. View the best growth stocks for 2024 here. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) issued its earnings results on Tuesday, August, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $2 million. Who are ARS Pharmaceuticals' major shareholders? Top institutional shareholders of ARS Pharmaceuticals include ClariVest Asset Management LLC (0.30%), Dimensional Fund Advisors LP (0.20%), Bank of New York Mellon Corp (0.14%) and Renaissance Technologies LLC (0.13%). Insiders that own company stock include Ra Capital Management, LP, Richard E Lowenthal, Sarina Tanimoto, Laura Shawver, Kathleen D Scott, Brian Dorsey and Eric Karas. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SPRY) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
